BIAF — bioAffinity Technologies, Inc.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for BIAF in the TickerWise workspace.

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Company profile

• Sector: Healthcare
• Industry: Medical - Diagnostics & Research
• Country: US
• Exchange: NASDAQ Capital Market
• Employees: 57
• Website: https://www.bioaffinitytech.com

Latest SEC filings for BIAF

• 2026-09-308-K
• 2026-09-228-K
• 2026-09-178-K
• 2026-09-118-K
• 2026-09-098-K
• 2026-09-08424B3
• 2026-09-038-K
• 2026-09-03S-3/A
• 2026-09-018-K
• 2026-08-27S-3

Latest BIAF news

• 2026-10-08BIAF Stock Draws Traders As CyPath Lung Growth Accelerates
• 2026-10-04UGRO, TURB, ANNA, EEIQ, BIAF: These Five Stocks Outpaced Big Tech With Massive March Returns

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.